Efficacy of Wharton Jelly Mesenchymal Stromal Cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial.

Fiche publication

Date publication

août 2023

Journal

Frontiers in medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BENSOUSSAN Danièle , Pr DE CARVALHO BITTENCOURT Marcelo , Pr DECOT Véronique , Dr POCHON Cécile , Dr REPPEL Loïc , Dr GAUTHIER Michaël

Tous les auteurs :
Pochon C, Laroye C, Kimmoun A, Reppel L, Dhuyser A, Rousseau H, Gauthier M, Petitpain N, Chabot JF, Valentin S, de Carvalho Bittencourt M, Peres M, Aarnink A, Decot V, Bensoussan D, Gibot S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37706025

Résumé

The COVID-19 pandemic caused a wave of acute respiratory distress syndrome (ARDS) with a high in-hospital mortality, especially in patients requiring invasive mechanical ventilation. Wharton Jelly-derived Mesenchymal Stromal Cells (WJ-MSCs) may counteract the pulmonary damage induced by the SARS-CoV-2 infection through pro-angiogenic effects, lung epithelial cell protection, and immunomodulation.